Stress Test in Detecting Heart Damage in Premenopausal Women With Stage I-III Breast Cancer
NCT03505736 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 25
Last updated 2026-01-29
Summary
This pilot trial studies how well a stress test works in detecting heart damage in premenopausal women with stage I-III breast cancer. Giving a stress test with adenosine or regadenoson and cardiovascular magnetic resonance imaging may help doctors detect heart damage caused by breast cancer treatments including chemotherapy and aromatase inhibitors.
Conditions
- Anatomic Stage I Breast Cancer AJCC v8
- Anatomic Stage IA Breast Cancer AJCC v8
- Anatomic Stage IB Breast Cancer AJCC v8
- Anatomic Stage II Breast Cancer AJCC v8
- Anatomic Stage IIA Breast Cancer AJCC v8
- Anatomic Stage IIB Breast Cancer AJCC v8
- Anatomic Stage III Breast Cancer AJCC v8
- Anatomic Stage IIIA Breast Cancer AJCC v8
- Anatomic Stage IIIB Breast Cancer AJCC v8
- Anatomic Stage IIIC Breast Cancer AJCC v8
- Premenopausal
- Prognostic Stage I Breast Cancer AJCC v8
- Prognostic Stage IA Breast Cancer AJCC v8
- Prognostic Stage IB Breast Cancer AJCC v8
- Prognostic Stage II Breast Cancer AJCC v8
- Prognostic Stage IIA Breast Cancer AJCC v8
- Prognostic Stage IIB Breast Cancer AJCC v8
- Prognostic Stage III Breast Cancer AJCC v8
- Prognostic Stage IIIA Breast Cancer AJCC v8
- Prognostic Stage IIIB Breast Cancer AJCC v8
- Prognostic Stage IIIC Breast Cancer AJCC v8
Interventions
- BIOLOGICAL
-
Adenosine
Given IV
- PROCEDURE
-
Magnetic Resonance Imaging
Undergo CMR imaging
- DRUG
-
Regadenoson
Given IV
- PROCEDURE
-
Stress Management Therapy
Undergo stress test
Sponsors & Collaborators
-
National Cancer Institute (NCI)
collaborator NIH -
Wake Forest University Health Sciences
lead OTHER
Principal Investigators
-
Emily Douglas · Wake Forest University Health Sciences
Eligibility
- Max Age
- 55 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-06-21
- Primary Completion
- 2020-03-05
- Completion
- 2020-03-05
Countries
- United States
Study Locations
More Related Trials
-
Neoadjuvant Letrozole in Treating Postmenopausal Women With Estrogen-Receptor Positive and/or Progesterone-Receptor Positive Stage II, Stage IIIA, or Stage IIIB Breast Cancer
NCT00084396 ·Status: COMPLETED ·Phase: PHASE2
-
Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy
NCT00053898 ·Status: COMPLETED ·Phase: PHASE3
-
Study on Pre-menopausal Patients With Advanced ER and PR + BC Treated With Arimidex Plus Zoladex
NCT00235937 ·Status: COMPLETED ·Phase: PHASE2
-
RO4929097 And Exemestane in Treating Pre- and Postmenopausal Patients With Advanced or Metastatic Breast Cancer
NCT01149356 ·Status: TERMINATED ·Phase: PHASE1
-
Short-term Impacts of Endocrine Therapy on Cardiovascular and Brain Health Outcomes in Breast Cancer
NCT06781762 ·Status: RECRUITING
-
Estradiol Suppression for the Treatment of Metastatic Breast Cancer in Premenopausal Women
NCT00186121 ·Status: COMPLETED ·Phase: PHASE2
-
The Effect of Aromatase Inhibitors on Cardiovascular Risk Factors in Women With Breast Cancer
NCT01080170 ·Status: COMPLETED
-
Neoadjuvant Hormonal Therapy Compared to Neoadjuvant Chemotherapy in Stage IIIB/C and IV Breast Cancer Patients
NCT02995772 ·Status: COMPLETED ·Phase: PHASE3
-
Tamoxifen Compared With LY353381 in Treating Women With Newly Diagnosed Breast Cancer
NCT00005886 ·Status: COMPLETED ·Phase: PHASE1
-
Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer
NCT03219476 ·Status: COMPLETED ·Phase: PHASE2
-
Individuals on Hormone Therapy Breast Cancer Screening Pilot
NCT06383026 ·Status: RECRUITING
-
Tamoxifen in Treating Women With High-Risk Breast Cancer
NCT00002542 ·Status: COMPLETED ·Phase: PHASE3
-
Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer
NCT02311933 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Dietary and Exercise Interventions in Reducing Side Effects in Patients With Stage I-IIIa Breast Cancer Receiving Aromatase Inhibitors
NCT03953157 ·Status: COMPLETED ·Phase: NA
-
Effect of Tamoxifen or an Aromatase Inhibitor on Estrogen Metabolism in Women Treated for Newly Diagnosed Breast Cancer
NCT00569543 ·Status: COMPLETED
-
RO4929097 and Letrozole in Treating Post-Menopausal Women With Hormone Receptor-Positive Stage II or Stage III Breast Cancer
NCT01208441 ·Status: TERMINATED ·Phase: PHASE1
-
Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer
NCT00066690 ·Status: COMPLETED ·Phase: PHASE3
-
Small-group, Virtual Program for Improving Symptoms and Distress Related to Hormonal Therapy for Breast Cancer Survivors
NCT03837496 ·Status: COMPLETED ·Phase: NA
-
Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery
NCT01953588 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Patient Reported Outcomes, Smart Pill Bottle and Teleheath for Endocrine Therapy Adherence
NCT04054557 ·Status: COMPLETED ·Phase: NA
-
Neoadjuvant and Adjuvant Exemestane in Treating Postmenopausal Women With Locally Advanced Hormone Receptor-Positive Breast Cancer
NCT00080613 ·Status: WITHDRAWN ·Phase: PHASE2
-
Identification and Evaluation of Patients at Risk of Developing Cardiotoxicity After Receiving Chemotherapy for Breast Cancer, Lymphoma or Leukemia
NCT04541212 ·Status: ACTIVE_NOT_RECRUITING
-
Anastrozole and ZD 1839 in Treating Postmenopausal Women With Metastatic Breast Cancer
NCT00049062 ·Status: COMPLETED ·Phase: PHASE2
-
Neoadjuvant DPX-Survivac Aromatase Inhibition, Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer
NCT04895761 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Trastuzumab With or Without Tamoxifen in Treating Women With Progressive Stage IV Breast Cancer
NCT00053339 ·Status: WITHDRAWN ·Phase: PHASE3